Emcure Pharmaceuticals (EMCURE) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 delivered strong all-round performance, with consolidated revenue up 22.8% year-over-year to INR 25,804 million and PAT up 36.2% to INR 2,925 million, reflecting robust international and resilient domestic growth.

• Leadership changes include Satish Mehta becoming Chairman and CEO, Samit Mehta appointed COO and CEO of Gennova Biopharmaceuticals, and full ownership consolidation of Gennova.

• Gennova Biopharmaceuticals is now a wholly-owned subsidiary, enhancing biologics and biosimilars capabilities.

• Strategic focus remains on execution, R&D-driven product launches, and international expansion.

• Q1 FY27 marks a strong start to the second year of the five-year plan, with broad-based growth across revenue, profitability, and earnings.

Financial highlights

• Revenue reached INR 25,804 million (up 22.8% YoY); international business contributed 58% of total revenue.

• EBITDA increased 25.8% YoY to INR 5,080 million, with margin improving to 19.7%, up 50 bps.

• PAT stood at INR 2,925 million, with margin at 11.3%, up 110 bps YoY.

• Gross profit margin was 58.4%, down 340 bps YoY due to higher international revenue share.

• R&D investment was INR 904 million (3.5% of revenue); CAPEX for Q1 FY27 was INR 1,168 million.

Outlook and guidance

• Management reiterates confidence in low to mid-teen revenue growth for FY27, with EBITDA margin expansion of 70-100 bps targeted.

• Product pipeline and new launches provide visibility for sustained medium-term growth.

• Organic domestic growth expected to align with or exceed industry growth from Q2 onwards, with acceleration in H2.

• Net debt expected to rise in Q2 due to acquisitions, with a target to become net cash by FY28.

• Gross margin guidance revised to around 59% for FY27, reflecting higher international mix.